162 related articles for article (PubMed ID: 36943159)
21. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.
Cabanlong CV; Russell LN; Fantegrossi WE; Prather PL
Toxicol Sci; 2022 Apr; 187(1):175-185. PubMed ID: 35201352
[TBL] [Abstract][Full Text] [Related]
22. Fourth generation of synthetic cannabinoid receptor agonists: a summary on the latest insights.
Malaca S; Tini A; Umani Ronchi F
Acta Biomed; 2022 Jan; 92(6):e2021546. PubMed ID: 35075053
[TBL] [Abstract][Full Text] [Related]
23. GC-MS Identification and Quantification of the Synthetic Cannabinoid MDMB-4en- PINACA in Cannabis-derived Material Seized in the Turin Metropolitan Area (Italy).
Gerace E; Seganti F; Di Corcia D; Vincenti M; Salomone A
Curr Pharm Des; 2022; 28(32):2618-2621. PubMed ID: 35658890
[TBL] [Abstract][Full Text] [Related]
24. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution.
Banister SD; Connor M
Handb Exp Pharmacol; 2018; 252():191-226. PubMed ID: 30105473
[TBL] [Abstract][Full Text] [Related]
25. Adding more "spice" to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists.
Alam RM; Keating JJ
Drug Test Anal; 2020 Mar; 12(3):297-315. PubMed ID: 31854124
[TBL] [Abstract][Full Text] [Related]
26. Saturated Cannabinoids: Update on Synthesis Strategies and Biological Studies of These Emerging Cannabinoid Analogs.
Docampo-Palacios ML; Ramirez GA; Tesfatsion TT; Okhovat A; Pittiglio M; Ray KP; Cruces W
Molecules; 2023 Sep; 28(17):. PubMed ID: 37687263
[TBL] [Abstract][Full Text] [Related]
27. Getting to the heart of cannabis health risks.
Sakmar TP
Cell; 2022 May; 185(10):1623-1625. PubMed ID: 35561662
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
Chung EY; Cha HJ; Min HK; Yun J
Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
[TBL] [Abstract][Full Text] [Related]
29. Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons.
Antonides LH; Cannaert A; Norman C; NicDáeid N; Sutcliffe OB; Stove CP; McKenzie C
Drug Test Anal; 2021 Mar; 13(3):628-643. PubMed ID: 33161649
[TBL] [Abstract][Full Text] [Related]
30. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM
Clin Toxicol (Phila); 2024 Jun; ():1-7. PubMed ID: 38934347
[TBL] [Abstract][Full Text] [Related]
31. Synthetic cannabinoid use among a sample of individuals enrolled in community-based recovery programs: Are synthetic cannabinoids actually preferred to other drugs?
Smith KE; Staton M
Subst Abus; 2019; 40(2):160-169. PubMed ID: 30457960
[No Abstract] [Full Text] [Related]
32. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
[TBL] [Abstract][Full Text] [Related]
34. On the duration of cannabis effects and the presence of THC in the body.
Mørland J; Bretteville-Jensen AL; Bramness JG
Addiction; 2023 Feb; 118(2):390-391. PubMed ID: 36331427
[No Abstract] [Full Text] [Related]
35. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
[TBL] [Abstract][Full Text] [Related]
36. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
Ricci V; Ceci F; Di Carlo F; Di Muzio I; Ciavoni L; Santangelo M; Di Salvo G; Pettorruso M; Martinotti G; Maina G
Psychiatry Res; 2023 Feb; 320():115053. PubMed ID: 36682093
[TBL] [Abstract][Full Text] [Related]
37. Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model.
Casey SL; Mitchell VA; Sokolaj EE; Winters BL; Vaughan CW
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955774
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Hasenoehrl C; Storr M; Schicho R
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):329-337. PubMed ID: 28276820
[TBL] [Abstract][Full Text] [Related]
39. Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
Craft S; Dunn M; Vidler D; Officer J; Blagbrough IS; Pudney CR; Henderson G; Abouzeid A; Dargan PI; Eddleston M; Cooper J; Hill SL; Roper C; Freeman TP; Thomas SHL
Addiction; 2022 Nov; 117(11):2899-2906. PubMed ID: 35665553
[TBL] [Abstract][Full Text] [Related]
40. Cannabimimetic effects of abused indazole-carboxamide synthetic cannabinoid receptor agonists AB-PINACA, 5F-AB-PINACA and 5F-ADB-PINACA in mice: Tolerance, dependence and withdrawal.
Wilson CD; Hiranita T; Fantegrossi WE
Drug Alcohol Depend; 2022 Jul; 236():109468. PubMed ID: 35643039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
